93 related articles for article (PubMed ID: 24492650)
1. Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
Latorre E; Castiglioni I; Gatto P; Carelli S; Quattrone A; Provenzani A
J Pharmacol Exp Ther; 2014 Apr; 349(1):99-106. PubMed ID: 24492650
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
3. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line.
AbuHammad S; Zihlif M
Genomics; 2013 Apr; 101(4):213-20. PubMed ID: 23201559
[TBL] [Abstract][Full Text] [Related]
4. Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs.
Díaz Bessone MI; Berardi DE; Campodónico PB; Todaro LB; Lothstein L; Bal de Kier Joffé ED; Urtreger AJ
Breast Cancer Res Treat; 2011 Apr; 126(3):577-87. PubMed ID: 20512658
[TBL] [Abstract][Full Text] [Related]
5. Translational control of TOP2A influences doxorubicin efficacy.
Srikantan S; Abdelmohsen K; Lee EK; Tominaga K; Subaran SS; Kuwano Y; Kulshrestha R; Panchakshari R; Kim HH; Yang X; Martindale JL; Marasa BS; Kim MM; Wersto RP; Indig FE; Chowdhury D; Gorospe M
Mol Cell Biol; 2011 Sep; 31(18):3790-801. PubMed ID: 21768308
[TBL] [Abstract][Full Text] [Related]
6. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
Yamochi T; Yamochi T; Aytac U; Sato T; Sato K; Ohnuma K; McKee KS; Morimoto C; Dang NH
Cancer Res; 2005 Mar; 65(5):1973-83. PubMed ID: 15753397
[TBL] [Abstract][Full Text] [Related]
7. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
8. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
Lee SA; Jung M
J Biol Chem; 2007 May; 282(20):15271-83. PubMed ID: 17371872
[TBL] [Abstract][Full Text] [Related]
9. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
10. Domain-specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) isotype-triggered activities of the RNA binding protein HuR.
Schulz S; Doller A; Pendini NR; Wilce JA; Pfeilschifter J; Eberhardt W
Cell Signal; 2013 Dec; 25(12):2485-95. PubMed ID: 23978401
[TBL] [Abstract][Full Text] [Related]
11. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
12. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
13. A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Kim HL; Jeon KH; Jun KY; Choi Y; Kim DK; Na Y; Kwon Y
Cancer Lett; 2012 Dec; 325(1):72-9. PubMed ID: 22732416
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway.
Lønne GK; Masoumi KC; Lennartsson J; Larsson C
J Biol Chem; 2009 Nov; 284(48):33456-65. PubMed ID: 19833733
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
Williams AO; Isaacs RJ; Stowell KM
BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
18. High-constitutive HuR phosphorylation at Ser 318 by PKC{delta} propagates tumor relevant functions in colon carcinoma cells.
Doller A; Winkler C; Azrilian I; Schulz S; Hartmann S; Pfeilschifter J; Eberhardt W
Carcinogenesis; 2011 May; 32(5):676-85. PubMed ID: 21310943
[TBL] [Abstract][Full Text] [Related]
19. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
20. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
